Regulatory T cell (CD4-positive, CD25-positive, FOXP3-positive) (Treg)

Regulatory T cells characterized by the co-expression of **CD4** and **CD25** surface markers along with the transcription factor **FOXP3** are a specialized subset within the immune system known as "Tregs." These cells play an essential role in maintaining immune homeostasis by suppressing excessive or misdirected immune responses that could lead to autoimmunity. They achieve this through multiple mechanisms including cytokine secretion (notably IL‑10, IL‑35, and transforming growth factor beta), direct suppression via CTLA‑4-mediated pathways, competition for interleukin 2, and inhibition of both adaptive effectors like cytotoxic lymphocytes as well as innate effectors such as natural killer cells. There are two main subtypes: "natural" regulatory T cells that develop in the thymus primarily to maintain self-tolerance; and "induced" regulatory T cells generated from conventional naïve CD4+ precursors outside the thymus under certain conditions—these help maintain tolerance toward environmental antigens. Elevated numbers have been observed in cancer patients where they contribute to tumor-induced immunosuppression; conversely, depletion leads to increased risk for autoimmune disorders. Their unique biology makes them a focus both as biomarkers for disease prognosis/monitoring and potential therapeutic targets—though manipulation carries significant safety risks due to their central role in preventing pathological immunity.

Other names

CD4+CD25+ regulatory T cellRegulatory T cell (Treg)CD4-positive, CD25-positive regulatory T cellFOXP3+ regulatory T cell

Depletion or inhibition of regulatory T cells to enhance anti-tumor immunity by blocking their suppressive effects on cytotoxic lymphocytes. Modulation via cytokines such as IL‑2, which is critical for both effector and regulatory populations; competition for IL‑2 is a key mechanism by which these cells regulate other immune responses.